Rhinovirus Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Rhinovirus Infections – Pipeline Review, H2 2019’, provides an overview of the Rhinovirus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhinovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infections

– The report reviews pipeline therapeutics for Rhinovirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Rhinovirus Infections therapeutics and enlists all their major and minor projects

– The report assesses Rhinovirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Rhinovirus Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rhinovirus Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Apollo Therapeutics LLC

AstraZeneca Plc

Biological Mimetics Inc

Collaborations Pharmaceuticals Inc

Enyo Pharma SA

Gilead Sciences Inc

Haplogen GmbH

Meissa Vaccines Inc

Polyrizon Ltd

PrEP Biopharm Ltd

Romark Laboratories LC

Sagimet Biosciences

Secarna Pharmaceuticals GmbH & Co. KG

ST Pharm Co Ltd

Symmune Therapeutics LLC

Viravaxx AG”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rhinovirus Infections Overview

Rhinovirus Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rhinovirus Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rhinovirus Infections Companies Involved in Therapeutics Development

3-V Biosciences Inc

AstraZeneca Plc

Biological Mimetics Inc

Enyo Pharma SA

Haplogen GmbH

Novartis AG

Prokarium Ltd

Romark Laboratories LC

ST Pharm Co., Ltd.

Rhinovirus Infections Drug Profiles

Antisense Oligonucleotide for Rhinovirus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNT-014 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetylpyridinium chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Enterovirus Infections and Rhinovirus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human rhinovirus (polyvalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KR-22809 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitazoxanide CR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OBR-5340 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-402 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polymer for Viral Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PrEP-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rhinovirus vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Rhinovirus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 3C Protease for Rhinovirus Infection Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PLA2G16 for Rhinovirus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVB-3567 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXX-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rhinovirus Infections Dormant Projects

Rhinovirus Infections Product Development Milestones

Featured News & Press Releases

May 10, 2017: Meissa announces award of NIH SBIR grant to support development of multivalent human rhinovirus vaccine candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Table 1: Number of Products under Development for Rhinovirus Infections, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Universities/Institutes, H2 2019

Table 6: Number of Products by Stage and Target, H2 2019

Table 7: Number of Products by Stage and Mechanism of Action, H2 2019

Table 8: Number of Products by Stage and Route of Administration, H2 2019

Table 9: Number of Products by Stage and Molecule Type, H2 2019

Table 10: Rhinovirus Infections – Pipeline by Apollo Therapeutics LLC, H2 2019

Table 11: Rhinovirus Infections – Pipeline by AstraZeneca Plc, H2 2019

Table 12: Rhinovirus Infections – Pipeline by Biological Mimetics Inc, H2 2019

Table 13: Rhinovirus Infections – Pipeline by Collaborations Pharmaceuticals Inc, H2 2019

Table 14: Rhinovirus Infections – Pipeline by Enyo Pharma SA, H2 2019

Table 15: Rhinovirus Infections – Pipeline by Gilead Sciences Inc, H2 2019

Table 16: Rhinovirus Infections – Pipeline by Haplogen GmbH, H2 2019

Table 17: Rhinovirus Infections – Pipeline by Meissa Vaccines Inc, H2 2019

Table 18: Rhinovirus Infections – Pipeline by Polyrizon Ltd, H2 2019

Table 19: Rhinovirus Infections – Pipeline by PrEP Biopharm Ltd, H2 2019

Table 20: Rhinovirus Infections – Pipeline by Romark Laboratories LC, H2 2019

Table 21: Rhinovirus Infections – Pipeline by Sagimet Biosciences, H2 2019

Table 22: Rhinovirus Infections – Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H2 2019

Table 23: Rhinovirus Infections – Pipeline by ST Pharm Co Ltd, H2 2019

Table 24: Rhinovirus Infections – Pipeline by Symmune Therapeutics LLC, H2 2019

Table 25: Rhinovirus Infections – Pipeline by Viravaxx AG, H2 2019

Table 26: Rhinovirus Infections – Dormant Projects, H2 2019

Table 27: Rhinovirus Infections – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Rhinovirus Infections, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports